CN
CN

Management Team

  • Ye HUA, MD, MPH

    CEO , Founder

    Ye HUA, MD, MPH

    CEO , Founder

    Dr. Hua is a seasoned drug developer who has 20 years’ global clinical development and new drug registration experience with track records. Prior to founding BioNova, Dr. Hua was Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchison MediPharma where he built up a development organization of 80+ employees across seven line functions with sites in Shanghai, Beijing, Guangzhou, Melbourne Australia and New Jersey USA. During his tenure at Hutchison MediPharma, Dr. Hua rapidly expanded development pipeline from five small molecules seven Phase 1 trials to eight small molecules for which half assets advanced to pivotal/registration trials. Dr. Hua led fruquintinib NDA submission in mCRC indication via MAH pilot policy in China and received regulatory approval. Native from Shanghai, Dr. Hua graduated from Fudan University Shanghai Medical College in 1992. He spent 16 years in the US in the field of clinical development with most significant achievements being regulatory submission and approval of Humira, Reclast/Aclasta, Zometa, Revlimid and Pomalyst.

  • Bryan HUANG, Ph.D., MBA

    CFO & Chief Strategy Officer,Co-Founder

    Bryan HUANG, Ph.D., MBA

    CFO & Chief Strategy Officer,Co-Founder

    Dr. Huang brings more than 20 years’ experience in medical research, pharmaceutic drug development and healthcare investment banking. Prior to co-founding BioNova, Dr. Huang was the Head of Business Development and Strategy at Immunomedics, responsible for all collaborations, licensing and acquisitions as well as development and portfolio strategy. Dr. Huang was previously BD and Portfolio Strategy Lead at Celgene for hematology and oncology franchise. He also worked as biotech equity analyst before joining pharmaceutical industry, covering 50+ companies across a variety of therapeutic areas with enstensive experience in primary and secondary stock underwriting and BD transactions totaled more than $20B.

  • Taishan HU, Ph.D.

    Head of Discovery

    Taishan HU, Ph.D.

    Head of Discovery

    Dr. Taishan Hu has extensive experience in the pharmaceutical industry as well as in academia. Medicinal chemist by training, Taishan brings over 20 years in small molecule drug discovery. He has a wealth of expertise in medicinal chemistry, patent strategies, project/people management, drug discovery strategies setting and execution. Experienced in oncology, cancer immunology, inflammation, CNS, and infectious disease, Taishan leads pre-clinical drug discovery organization of the company, by evaluating and initiating new projects, designing and inventing novel chemical entities towards PCCs and INDs. Prior to joining BioNova, Taishan served as the Site Head of Shanghai Institute of Drug Discovery, Zhejiang Hisun Pharmaceutical Company where he built up a multi-disciplinary drug discovery team and successfully delivered several preclinical drug candidates to IND. Prior to Hisun, Taishan was a Principle Scientist at Roche R&D (China) Center. Taishan published over 30 peer-reviewed articles and over 30 patents. Taishan received his Ph. D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.

  • Winnie WU

    Head of Operations

    Winnie WU

    Head of Operations

    Winnie joined BioNova as Head of Operations in 2019. Under her leadership in talent acquisition and office administration, BioNova has advanced to fast growth stage with well-balanced staffing situation. Winnie has more than 10 years of pharmaceutical industry experience. Prior to joining BioNova, Winnie was HR & Admin manager at Pivotal BioVenture Partners where she was responsible for company payroll, employee relationship, talent management, Culture and team building, government affairs, general administration and IT management. Practiced in labor law and building HR working process. Earlier in her career, Winnie worked in the HR field at I-Bridge Capital and Hutchsion MediPharma. Winnie received a Bachelor Degree in Business Administration from Shanghai Normal University.

  • Yu WANG

    Head of Hematology, Clinical Development

    Yu WANG

    Head of Hematology, Clinical Development

    Yu joined BioNova in early 2020. As a card-carrying hematologist, Yu successfully led the cGVHD project IND filing and subsequently received Breakthrough Designation in China. Yu graduated from Tongji Medical College, Huazhong University of Science and Technology. She specialized in hematology and worked as resident and attending physician for 8 years prior to joining the pharmaceutical industry. Then she worked in Sanofi, Roche, Hutchison and Fosunkite. Through many years of extensive experience, as a physician scientist, Yu devoted in clinical development for target therapies and CAR-T cell therapy for hematologic malignancies, effective leader of cross-functional teams driving complex projects and solving multifaceted problem, and successfully led the clinical development program and the NDA filing of Yescarta, which is the first approved CAR-T cell therapy in China.

  • Peng WANG

    CMC Director

    Peng WANG

    CMC Director

    Peng joinined BioNova in early 2021. He has more than 15 years’ experience in CMC research and development, having led more than a dozen drugs to go through different research stages (IND-NDA). Works closely with cross-functional, and at the corporate level(including R&D,clinical operation, clinical affairs and quality assurance) to identify issues that may impact project milestone or business operations, and recommends appropriate action to be taken. Lead CMC development at different stages of process development, formulation development, clinical trial manufacturing, product characterization and process validation. Set up Quality Management System as well as monitoring and optimizing the system. Prior to Joining BioNova, Peng worked at AnHeart and Haihe BioPharma. Peng graduated from East China University of Science and Technology.

  • Jenny DENG

    Associate Director, Drug Discovery

    Jenny DENG

    Associate Director, Drug Discovery

    Jenny joinined BioNova in early 2021. She graduated from University of Liverpool with the Bachelor of Science and obtained Master of Science degree from McGill University. Prior to joining BioNova, Jenny was senior project manager at Jiangsu Hengrui Medicine, responsible for IND-enabling projects including designed, executed and interpreted non-clinical pharmacology, ADME and toxicology studies, and completed the IND and NDA for several new drugs.

  • Cindy CHENG, MBA

    Senior Director, Business Development & Strategy

    Cindy CHENG, MBA

    Senior Director, Business Development & Strategy

    Cindy joinined BioNova in early 2021. She holds a BS degree from China Pharmaceutical University, MBA from Fudge-MIT program and master of law from Renmin University. Prior to joining BioNova, she has 10+ years' BD experience in pharmaceutical industry, serving in LUYE, HISUN and Shanghai Jemincare. She has led or participated BD projects of both chemical and biological innovations, including Avigan from Fujifilm and etc. Before she also acted as bio-science industry specialist for MCC for 5+ years.

  • Xiaorui WANG Ph.D.

    Director, Project Management

    Xiaorui WANG Ph.D.

    Director, Project Management

    Xiaorui Wang joined BioNova in mid-2021. She graduated from National University of Singapore with a Bachelor of Science Degree in Life Science and a PhD in biochemistry. Prior to joining BioNova, Xiaorui was VP of ZENSUN Shanghai, responsible for local and global clinical development and regulatory affairs for first-in-class biological drugs and 505(b)(2) drugs, including drug development strategy, clinical operation, medical affairs, pharmacovigilance, and regulatory affairs.

  • Fang LIU, Ph.D.

    Director, Translational Medicine

    Fang LIU, Ph.D.

    Director, Translational Medicine

    Fang joined BioNova in September 2021. She has over 10 years of translational medicine experience including extensive experience in biomarker development for immuno-oncology and cell therapy. Prior to joining BioNova, Fang worked as Biomarker Leader at Innovent and BeiGene and supported several mAbs, bispecific antibodies and small molecules’ clinical development. Before BeiGene, Fang served as Research Scientist at Cellular Biomedicine Group and Institute Merieux (BioMerieux and Transgene), focusing on biomarker and bioassay discovery, development and testing. Fang holds a Ph.D. in Pharmacology from Shanghai Jiao Tong University and a Bachelor’s degree of Clinical Medicine from Jilin Medical College.

  • Wei WU

    Director, Quality Assurance

    Wei WU

    Director, Quality Assurance

    Wei Wu joined BioNova in end of 2021. Wei has more than 20 years’ experience in the pharmaceutical industry in which he worked through the ranks at big pharma companies BMS, Roche, Daiichi-Sankyo, Johnson & Johnson and Bayer. He has extensive QC and QA knowledge in CMC area covering multiple types of formulation, such as tablet, capsule, syrup, cream, lotion and injectables. During his tenure at Bayer, Wei contributed to the Shanghai site transformation from a typical manufacturing plant to a full-functional MAH holder.

    Wei received his Bachelor Degree of Engineering from Shanghai University and a Master Degree of Industrial Engineering from Tongji University.


  • Xin CHEN Ph.D.

    Director, Clinical Pharmacology

    Xin CHEN Ph.D.

    Director, Clinical Pharmacology

    Xin joined BioNova in December 2021. She has over 10 years’ experience in Clinical Pharmacology /DMPK and participated in multiple new drug projects from drug discovery to clinical development.  Prior to joining BioNova, Xin worked through the ranks in Clin Pharm/DMPK at her previous jobs with Abbisko, Hansoh Pharm, Viva and Covance. She received Ph.D. degree in chemistry from University of Utah and Bachelor’s degree from University of Science and Technology of China.

  • Alex HUANG Ph.D.

    Senior Director, Regulatory Affairs

    Alex HUANG Ph.D.

    Senior Director, Regulatory Affairs

    Dr. Huang graduated from Shanghai Jiao Tong University (PhD), and Shanghai Institute of Pharmaceutical Industry (MS). He has more than 20 years’ comprehensive experience in the pharmaceutical industry, including in regulatory affairs, CMC quality, clinical trial, project management, and R&D operations.

    Prior to joining BioNova, Dr. Huang was former R&D Deputy General Manager at Sinopharm Shanghai Shyndec Pharmaceutical, and former Head of Regulatory Affairs at Aurobindo Pharma (China) and TYK Medicines. He led the development and market authorization applications for over a dozen generic drugs in China as well as China & US IND applications for multiple innovative new drugs.